Although the clinical relevance on the aforementioned cardiovascular threat factor alterations by tirzepatide might be assessed from the planned cardiovascular result study SURPASS-CVOT ( "form":"clinical-trial","attrs": "textual content":"NCT04255433","term_id":"NCT04255433" NCT04255433), a pre-specified cardiovascular meta-analysis indicated that